NEWS

NEWS

Total 102

42
NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection
2021-07-26
41
NeoImmuneTech Trial Data Presented at American Society of Clinical Oncology Annual Meeting
2021-06-08
40
NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)
2021-06-08
39
NeoImmuneTech Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
2021-05-25
38
NeoImmuneTech to Present Two Posters at American Society of Clinical Oncology Annual Meeting
2021-05-20
37
NeoImmuneTech Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) in Patients with High Grade Glioma
2021-03-30
36
NeoImmuneTech Announces First Patient Dosed in Phase 2a Portion of Basket Study Evaluating NT-I7 (efineptakin alfa) and KEYTRUDA® (pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors
2021-03-23
35
NeoImmuneTech Announces Closing of Initial Public Offering
2021-03-16
34
NeoImmuneTech Appoints Byung Ha Lee, Ph.D., as Chief Scientific Officer
2021-03-01
33
NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
2021-02-23

<<<6 7 8 9 10 >>>